Alyssa J Moroi1, Peter J Newman1,2,3. 1. Blood Research Institute, Versiti Blood Center of Wisconsin, Milwaukee, Wisconsin, USA. 2. Department of Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 3. Department of Cell Biology, Neurobiology, and Anatomy, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Abstract
BACKGROUND: Thrombocytopenia leading to life-threatening excessive bleeding can be treated by platelet transfusion. Currently, such treatments are totally dependent on donor-derived platelets. To support future applications in the use of in vitro-derived platelets, we sought to identify genes whose manipulation might improve the efficiency of megakaryocyte production and resulting hemostatic effectiveness. Disruption of Lyn kinase has previously been shown to improve cell survival, megakaryocyte ploidy and TPO-mediated activation in mice, but its role in human megakaryocytes and platelets has not been examined. METHODS: To analyze the role of Lyn at defined differentiation stages during human megakaryocyte differentiation, conditional Lyn-deficient cells were generated using CRISPR/Cas9 technology in iPS cells. The efficiency of Lyn-deficient megakaryocytes to differentiate and become activated in response to a range of platelet agonists was analyzed in iPSC-derived megakaryocytes. RESULTS: Temporally controlled deletion of Lyn improved the in vitro differentiation of hematopoietic progenitor cells into mature megakaryocytes, as measured by the rate and extent of appearance of CD41+ CD42+ cells. Lyn-deficient megakaryocytes also demonstrated improved hemostatic effectiveness, as reported by their ability to mediate clot formation in rotational thromboelastometry. Finally, Lyn-deficient megakaryocytes produced increased numbers of platelet-like particles (PLP) in vitro. CONCLUSIONS: Conditional deletion of Lyn kinase increases the hemostatic effectiveness of megakaryocytes and their progeny as well as improving their yield. Adoption of this system during generation of in vitro-derived platelets may contribute to both their efficiency of production and their ability to support hemostasis.
BACKGROUND: Thrombocytopenia leading to life-threatening excessive bleeding can be treated by platelet transfusion. Currently, such treatments are totally dependent on donor-derived platelets. To support future applications in the use of in vitro-derived platelets, we sought to identify genes whose manipulation might improve the efficiency of megakaryocyte production and resulting hemostatic effectiveness. Disruption of Lyn kinase has previously been shown to improve cell survival, megakaryocyte ploidy and TPO-mediated activation in mice, but its role in human megakaryocytes and platelets has not been examined. METHODS: To analyze the role of Lyn at defined differentiation stages during human megakaryocyte differentiation, conditional Lyn-deficient cells were generated using CRISPR/Cas9 technology in iPS cells. The efficiency of Lyn-deficient megakaryocytes to differentiate and become activated in response to a range of platelet agonists was analyzed in iPSC-derived megakaryocytes. RESULTS: Temporally controlled deletion of Lyn improved the in vitro differentiation of hematopoietic progenitor cells into mature megakaryocytes, as measured by the rate and extent of appearance of CD41+ CD42+ cells. Lyn-deficient megakaryocytes also demonstrated improved hemostatic effectiveness, as reported by their ability to mediate clot formation in rotational thromboelastometry. Finally, Lyn-deficient megakaryocytes produced increased numbers of platelet-like particles (PLP) in vitro. CONCLUSIONS: Conditional deletion of Lyn kinase increases the hemostatic effectiveness of megakaryocytes and their progeny as well as improving their yield. Adoption of this system during generation of in vitro-derived platelets may contribute to both their efficiency of production and their ability to support hemostasis.
Authors: R Guerriero; G Mattia; U Testa; C Chelucci; G Macioce; I Casella; P Samoggia; C Peschle; H J Hassan Journal: Blood Date: 2001-05-01 Impact factor: 22.113
Authors: L S Quek; J M Pasquet; I Hers; R Cornall; G Knight; M Barnes; M L Hibbs; A R Dunn; C A Lowell; S P Watson Journal: Blood Date: 2000-12-15 Impact factor: 22.113
Authors: Yotis A Senis; Michael G Tomlinson; Angel García; Stephanie Dumon; Victoria L Heath; John Herbert; Stephen P Cobbold; Jennifer C Spalton; Sinem Ayman; Robin Antrobus; Nicole Zitzmann; Roy Bicknell; Jon Frampton; Kalwant S Authi; Ashley Martin; Michael J O Wakelam; Stephen P Watson Journal: Mol Cell Proteomics Date: 2006-12-23 Impact factor: 5.911
Authors: Bijender Kumar; Vahid Afshar-Kharghan; Mayela Mendt; Robert Sackstein; Mark R Tanner; Uday Popat; Jeremy Ramdial; May Daher; Juan Jimenez; Rafet Basar; Luciana Melo Garcia; Mayra Shanley; Mecit Kaplan; Xinhai Wan; Vandana Nandivada; Francia Reyes Silva; Vernikka Woods; April Gilbert; Ricardo Gonzalez-Delgado; Sunil Acharya; Paul Lin; Hind Rafei; Pinaki Prosad Banerjee; Elizabeth J Shpall Journal: Front Immunol Date: 2022-09-20 Impact factor: 8.786